Abatacept for Severe Immune Checkpoint Inhibitor–Associated Myocarditis
Open accessAbstract
Abatacept for Nivolumab-Induced Myocarditis Autoimmune myocarditis is a rare but often fatal complication of immune checkpoint inhibitor therapy for cancer. A case of glucocorticoid-refractory myoc...
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Abatacept alone or in combination with ruxolitinib has demonstrated clinical benefits in treating patients with ICI myocarditis and murine models.
“Additionally, as previously discussed, abatacept alone or in combination with ruxolitinib has demonstrated clinical benefits in treating patients with ICI myocarditis and murine models (Figure 2). 51,254,260”
From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [260]
In “Abatacept for Severe Immune Checkpoint Inhibitor–Associated Myocarditis” (page not provided), the authors report improvement after abatacept in one patient with ICI-associated myocarditis. The paper does not report treatment with ruxolitinib or results in murine models; its mention of preclinical studies is not evidence of those claimed results in this paper. (LLM, conf=0.88)
Experimental — accuracy not yet measuredIn steroid-refractory ICI myocarditis, abatacept, alemtuzumab, and antithymocyte globulin have been used in case reports.
“In cases refractory to steroids, other immunomodulators, including abatacept (a CTLA-4 agonist), alemtuzumab (anti-CD52 antibody), and antithymocyte globulin (antiCD3 antibody) have been used in case reports.”
From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [260]
In “Abatacept for Severe Immune Checkpoint Inhibitor–Associated Myocarditis” (page not provided), the authors report a case in which abatacept, a CTLA-4 agonist, was used for glucocorticoid-refractory ICI myocarditis. Our copy does not report case use of alemtuzumab or antithymocyte globulin, so it supports only the abatacept portion of the claim. (LLM, conf=0.90)
Experimental — accuracy not yet measuredRecent studies implemented pathogenic T cells as potential diagnostic or therapeutic targets for autoimmune myocarditis including ICI myocarditis, demonstrating promising outcomes at both clinical and preclinical levels.
“Recent studies implemented pathogenic T cells as potential diagnostic or therapeutic targets for autoimmune myocarditis including ICI myocarditis, demonstrating promising outcomes at both clinical and preclinical levels. 51,64,238,254,260,311,312”
From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [260]
A murine model of myocarditis provided a rationale for using CTLA4-Ig (abatacept) to block T-cell costimulation.
“For example, the recent development of a murine model of myocarditis, one of the most feared complications of ICT, provided a rationale for the use of CTLA4-Ig (abatacept), which blocks T-cell costimulation, although an open question remains as to whether this will interfere with antitumor immunity (97,98).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [98]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713 · see citing works
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609214 · Cited by 2,308 · see citing works
Self-citationSalem, J.-E., Manouchehri, A., Moey, M., Lebrun-Vignes, B., Bastarache, L., Pariente, A., Gobert, A., Spano, J.-P., Balko, J. M., Bonaca, M. P., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30608-9 · Cited by 1,271 · see citing works
Self-citationIncreased reporting of fatal immune checkpoint inhibitor-associated myocarditis
Moslehi, J. J., Salem, J.-E., Sosman, J. A., Lebrun-Vignes, B., & Johnson, D. B. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30533-6 · Cited by 942 · see citing works
Self-citationImmunosuppression — The Promise of Specificity
Ingelfinger, J. R., & Schwartz, R. S. (2005) · New England Journal of Medicine · doi:10.1056/nejme058166 · Cited by 37 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Immune-checkpoint inhibitors: long-term implications of toxicity
Johnson, D. B., Nebhan, C. A., Moslehi, J. J., & Balko, J. M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00600-w · Cited by 982 · see citing works
Self-citationAmmirati, E., Frigerio, M., Adler, E. D., Basso, C., Birnie, D. H., Brambatti, M., Friedrich, M. G., Klingel, K., Lehtonen, J., Moslehi, J. J., et al. (2020) · Circulation: Heart Failure · doi:10.1161/circheartfailure.120.007405 · Cited by 811 · see citing works
Self-citationThe Next Decade of Immune Checkpoint Therapy
Sharma, P., Siddiqui, B. A., Anandhan, S., Yadav, S. S., Subudhi, S. K., Gao, J., Goswami, S., & Allison, J. P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1680 · Cited by 750 · see citing works
Kociol, R. D., Cooper, L. T., Fang, J. C., Moslehi, J. J., Pang, P. S., Sabe, M. A., Shah, R. V., Sims, D. B., Thiene, G., Vardeny, O., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000745 · Cited by 625 · see citing works
Self-citationPalaskas, N., Lopez‐Mattei, J., Durand, J. B., Iliescu, C., & Deswal, A. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.013757 · Cited by 535 · see citing works
T cells specific for α-myosin drive immunotherapy-related myocarditis
Axelrod, M. L., Meijers, W. C., Screever, E. M., Qin, J., Carroll, M. G., Sun, X., Tannous, E., Zhang, Y., Sugiura, A., Taylor, B. C., et al. (2022) · Nature · doi:10.1038/s41586-022-05432-3 · Cited by 367 · see citing works
Self-citationMoving towards personalized treatments of immune-related adverse events
Esfahani, K., Elkrief, A., Calabrese, C., Lapointe, R., Hudson, M., Routy, B., Miller, W. H., & Calabrese, L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0352-8 · Cited by 351 · see citing works
Understanding and treating the inflammatory adverse events of cancer immunotherapy
Dougan, M., Luoma, A. M., Dougan, S. K., & Wucherpfennig, K. W. (2021) · Cell · doi:10.1016/j.cell.2021.02.011 · Cited by 319 · see citing works
Wei, S. C., Meijers, W. C., Axelrod, M. L., Anang, N.-A. A. S., Screever, E. M., Wescott, E. C., Johnson, D. B., Whitley, E., Lehmann, L., Courand, P.-Y., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0856 · Cited by 290 · see citing works
Self-citationImmune checkpoint inhibitor–associated myocarditis: manifestations and mechanisms
Moslehi, J., Lichtman, A. H., Sharpe, A. H., Galluzzi, L., & Kitsis, R. N. (2021) · Journal of Clinical Investigation · doi:10.1172/jci145186 · Cited by 237 · see citing works
Self-citationExpansion of Pathogenic Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis
Ma, P., Liu, J., Qin, J., Lai, L., Heo, G. S., Luehmann, H., Sultan, D., Bredemeyer, A., Bajapa, G., Feng, G., et al. (2024) · Circulation · doi:10.1161/circulationaha.122.062551 · Cited by 187 · see citing works
Self-citationLehmann, L. H., Cautela, J., Palaskas, N., Baik, A. H., Meijers, W. C., Allenbach, Y., Alexandre, J., Rassaf, T., Müller, O. J., Aras, M., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.2241 · Cited by 178 · see citing works
Self-citationElectrocardiographic Manifestations of Immune Checkpoint Inhibitor Myocarditis
Power, J. R., Alexandre, J., Choudhary, A., Ozbay, B., Hayek, S., Asnani, A., Tamura, Y., Aras, M., Cautela, J., Thuny, F., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.055816 · Cited by 136 · see citing works
Self-citationImmune checkpoint inhibitors associated cardiovascular immune-related adverse events
Jo, W., Won, T., Daoud, A., & Čiháková, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1340373 · Cited by 55 · see citing works
Autoimmune Myocarditis, Old Dogs and New Tricks.
Won, T., Song, E. J., Kalinoski, H. M., Moslehi, J. J., & Čiháková, D. (2024) · Circulation Research · doi:10.1161/circresaha.124.323816 · Cited by 51 · see citing works
Self-citationSeethapathy, H., Mistry, K., & Sise, M. E. (2023) · Immunological Reviews · doi:10.1111/imr.13243 · Cited by 15 · see citing works
- Authors
- Salem, J.-E., Allenbach, Y., Vozy, A., Brechot, N., Johnson, D. B., Moslehi, J. J., & Kerneis, M.
- Affiliations
- Sorbonne Université (FR)
- Inserm (FR)
- Assistance Publique–Hôpitaux de Paris, Paris, France
- Vanderbilt University Medical Center (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-06-13
- Volume
- 380
- Issue
- 24
- Pages
- 2377-2379
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2950056455
- Semantic Scholar
- 5e86604e3abafdff6872334c652a2ccb500256b9
- Cited by
- 443
- References
- 5
- Citations by year
- 2026: 52 · 2025: 35 · 2024: 55 · 2023: 58 · 2022: 66 · 2021: 74 · 2020: 84 · 2019: 17
- FWCI
- 25.18
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Viral Infections and Immunology Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac tumors and thrombi
- Keywords
- abatacept, immune checkpoint inhibitors, immune checkpoint inhibitor-associated myocarditis, severe myocarditis, immune checkpoint inhibitor toxicity, IL-2 receptor blockade
- MeSH terms
- Abatacept, Antineoplastic Agents, Immunological, Nivolumab, Aged, Female, Humans, Immunosuppressive Agents, Lung Neoplasms, Myocarditis, Myositis, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
